MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Business”), a scientific phase pharmaceutical firm devoted to expanding healthy and balanced lifespan, today introduced that the first individual has been enlisted in the Company’s Stage 2 scientific trial of lead prospect MYMD-1, a dental immune regulator medicine, as a treatment for delaying aging and also increasing healthy and balanced life expectancy.
The primary endpoint for the Stage 2 double-blind, placebo-controlled professional trial is to attain a decrease in the circulating levels of (TNF-α), tumor death factor receptor I (TNFRI) as well as IL-6. TNF-α as well as IL-6 are the healthy proteins in the body that cause inflammation and assist trigger the procedure of aging. The secondary steps of the test will be the safety and security, tolerability, as well as pharmacokinetics in this population of patients.
” In a Stage 1 scientific trial of MYMD-1, we showed the medicine’s statistically considerable efficiency in decreasing levels of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has authorized TNF-α decrease as the primary endpoint for our Phase 2 research study, which our team believe settings us well for an effective Phase 2 outcome,” claimed Chris Chapman, M.D., President, Director as well as Chief Medical Police Officer of MyMD. “The initiation of individual registration in this study developments our mission to reduce the aging procedure, protect against loss of muscle cells in aging, limitation frailty, and also prolong healthy life expectancy.”
MyMD has stated that there are no FDA-approved drugs for dealing with aging problems as well as extending healthy and balanced life-span human beings, a market expected to be a minimum of $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are one of the most prescribed drugs by income, a global market of about $40 billion per year,2 and also, according to Nature Aging journal,3 a downturn in aging that would enhance life expectancy by one year is worth $38 trillion and by ten years deserves $367 trillion.
In addition to aging, MYMD-1’s distinct action in managing the immune system as well as dealing with persistent inflammation is being developed for the therapy of autoimmune illness, including rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes mellitus, and inflammatory digestive tract condition.
” We plan to begin creating methods for a Phase 2 pilot research of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The increasing prevalence of rheumatoid arthritis as well as other autoimmune and also inflammatory conditions are driving need for TNF inhibitors like MYMD-1, as well as our company believe our by mouth administered medicine with very reduced toxicity would be disruptive to the $60 billion market for RA if accepted by the FDA for this sign.”
Rheumatoid joint inflammation affects about 40 million individuals globally.4.
Initially developed for autoimmune diseases, MYMD-1’s main purpose is to slow down the aging procedure, prevent sarcopenia and frailty, as well as extend healthy and balanced lifespan. Since it can cross the blood-brain obstacle and get to the central nerves (CNS), MYMD-1 is likewise placed to be a possible therapy for brain-related disorders. Its system of activity and effectiveness in diseases consisting of numerous sclerosis (MS) and also thyroiditis have actually been examined with collaborations with several academic establishments. MYMD-1 is likewise showing pledge in pre-clinical studies as a possible treatment for post- COVID-19 complications and also as an anti-fibrotic and anti-proliferation therapeutic.
MYMD-1 has revealed efficiency in pre-clinical studies in managing the body immune system by executing as a selective prevention of growth death factor-alpha (TNF-α), a chauffeur of chronic inflammation. Unlike other treatments, MYMD-1 has been displayed in these pre-clinical research studies to uniquely block TNF-α when it comes to be overactivated in autoimmune diseases as well as cytokine storms, however not block it from doing its typical job of being a very first -responder to any regular type of moderate infection. MYMD-1’s ease of oral application is an additional differentiator contrasted to presently offered TNF-α blockers, every one of which need distribution by shot or mixture. No approved TNF prevention has actually ever been dosed by mouth. In addition, the medication is not immunosuppressive as well as has actually not been shown to cause the significant side effects usual with traditional therapies that treat inflammation.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company dedicated to expanding healthy life-span, is focused on creating 2 novel therapeutic platforms that deal with the causes of illness as opposed to just addressing the signs. MYMD-1 is a medicine platform based upon a clinical phase small particle that controls the immune system to control TNF-α, which drives persistent swelling, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, boost long life, and deal with autoimmune illness as well as COVID-19- linked anxiety. The Firm’s second medication platform, Supera-CBD, is being developed to deal with chronic discomfort, addiction as well as epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and is being created to attend to and surpass the quickly growing CBD market, which includes both FDA authorized medications and also CBD items not presently controlled as medications. For additional information, go to www.mymd.com.